NCT05325346 is a Phase 1 clinical trial of VLX-1005 in Heparin-induced Thrombocytopenia, sponsored by Veralox Therapeutics.

Who is sponsoring NCT05325346?

NCT05325346 is sponsored by Veralox Therapeutics.

What drugs are being tested in NCT05325346?

Interventions in NCT05325346: VLX-1005, Argatroban.

What condition does NCT05325346 study?

NCT05325346 studies Heparin-induced Thrombocytopenia.

Is NCT05325346 still recruiting?

NCT05325346 is currently completed. Last updated 11 January 2023.

Last reviewed 2023-01-11 · How we verify

NCT05325346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Completed Phase 1 Last updated 11 January 2023

What this trial tests

Phase 1 trial testing VLX-1005 in Heparin-induced Thrombocytopenia in 12 participants. Completed in 14 April 2022.

Timeline

7 March 2022

Primary endpoint
1 April 2022

14 April 2022

Quick facts

Lead sponsor	Veralox Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	7 March 2022
Primary completion	1 April 2022
Estimated completion	14 April 2022
Sites	1 location across United States

Drugs / interventions tested

VLX-1005 — full drug profile →
Argatroban (ARGATROBAN) — full drug profile →

Conditions studied

Heparin-induced Thrombocytopenia — all drugs for Heparin-induced Thrombocytopenia →

Sponsor

Veralox Therapeutics

Who can join

Adults 19 to 55, any sex, with Heparin-induced Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia.
Yamaguchi A, Putzbach V, Adili R, Lazar S, et al · · 2026 · PMID 41909515 · DOI 10.1016/j.bvth.2026.100146

Verify or expand the search:

Other trials of VLX-1005

Trials testing the same drug.

NCT05785819 — A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia · Phase 2 · terminated
NCT04783545 — Phase I Study of VLX-1005 in Healthy Subjects · Phase 1 · completed

Other Veralox Therapeutics trials

Trials by the same sponsor.

NCT05785819 — A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia · Phase 2 · terminated
NCT04783545 — Phase I Study of VLX-1005 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05325346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Veralox Therapeutics
Last refreshed: 11 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05325346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing